MX378739B - Compuestos de 2-oxindol. - Google Patents

Compuestos de 2-oxindol.

Info

Publication number
MX378739B
MX378739B MX2018008895A MX2018008895A MX378739B MX 378739 B MX378739 B MX 378739B MX 2018008895 A MX2018008895 A MX 2018008895A MX 2018008895 A MX2018008895 A MX 2018008895A MX 378739 B MX378739 B MX 378739B
Authority
MX
Mexico
Prior art keywords
oxindol
compounds
oxindol compounds
mediatedconditions
ccr
Prior art date
Application number
MX2018008895A
Other languages
English (en)
Other versions
MX2018008895A (es
Inventor
Chao Yu
Dean R Dragoli
Hiroko Tanaka
Jay P Powers
Ju Yang
Manmohan Reddy Leleti
Penglie Zhang
Pingchen Fan
Rajinder Singh
Rebecca M Lui
Viengkham Malathong
Xi Chen
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2018008895A publication Critical patent/MX2018008895A/es
Publication of MX378739B publication Critical patent/MX378739B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Se proporcionan compuestos de oxindol útiles para el tratamiento de afecciones o enfermedades mediadas por CCR(9).
MX2018008895A 2016-01-20 2017-01-18 Compuestos de 2-oxindol. MX378739B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662280969P 2016-01-20 2016-01-20
PCT/US2017/013899 WO2017127409A1 (en) 2016-01-20 2017-01-18 2-oxindole compounds

Publications (2)

Publication Number Publication Date
MX2018008895A MX2018008895A (es) 2019-02-13
MX378739B true MX378739B (es) 2025-03-11

Family

ID=59314376

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008895A MX378739B (es) 2016-01-20 2017-01-18 Compuestos de 2-oxindol.

Country Status (18)

Country Link
US (5) US20170204087A1 (es)
EP (1) EP3405455B1 (es)
JP (1) JP6898334B6 (es)
KR (1) KR102799183B1 (es)
CN (1) CN108698991B (es)
AR (1) AR107398A1 (es)
AU (1) AU2017209023B2 (es)
BR (1) BR112018014666B1 (es)
ES (1) ES2985738T3 (es)
IL (1) IL260635B (es)
MA (1) MA43799A (es)
MX (1) MX378739B (es)
NZ (1) NZ744468A (es)
RU (1) RU2743747C2 (es)
SG (1) SG11201806153QA (es)
TW (1) TWI729059B (es)
WO (1) WO2017127409A1 (es)
ZA (1) ZA201804966B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102799183B1 (ko) 2016-01-20 2025-04-21 케모센트릭스, 인크. 2-옥신돌 화합물
WO2019246312A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2021007386A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
BR112022006279A2 (pt) 2019-10-16 2022-06-28 Chemocentryx Inc Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
JP7283567B2 (ja) * 2019-10-21 2023-05-30 信越化学工業株式会社 感光性樹脂組成物、感光性ドライフィルム及びパターン形成方法
WO2021084068A1 (en) * 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
CA3233658A1 (en) * 2021-10-06 2023-04-13 Ursula Gompels Novel immune regulator

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
FR2686878B1 (fr) * 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
KR100281867B1 (ko) 1996-01-17 2001-02-15 고바야시 유키오 3-(비스-치환페닐메틸렌)옥신돌유도체
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
FR2807038B1 (fr) * 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
WO2003078394A1 (en) 2002-03-15 2003-09-25 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
DK1798223T4 (da) * 2002-11-18 2014-09-22 Chemocentryx Inc Arylsulfonamider
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
FR2909668B1 (fr) * 2006-12-12 2009-01-23 Sanofi Aventis Sa Derives de 5-alkyloxy-indolin-2-one,leur preparation et leurs applications en therapeutique
CA2676145A1 (en) * 2007-02-06 2008-08-14 Novartis Ag 1-benzenesulfonyl-1h-indole derivatives as inhibitors of ccr9 activity
WO2010045251A2 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2011069298A1 (en) * 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
ES2816060T3 (es) * 2012-02-29 2021-03-31 Chemocentryx Inc Aza-aril 1H-pirazol-1-il-bencenosulfonamidas como antagonistas de CCR(9)
US9715915B2 (en) 2014-10-30 2017-07-25 Samsung Electronics Co., Ltd. Magneto-resistive devices including a free layer having different magnetic properties during operations
KR102799183B1 (ko) 2016-01-20 2025-04-21 케모센트릭스, 인크. 2-옥신돌 화합물

Also Published As

Publication number Publication date
NZ744468A (en) 2022-07-01
AU2017209023A1 (en) 2018-08-09
EP3405455A4 (en) 2019-07-24
JP6898334B2 (ja) 2021-07-07
US11434230B2 (en) 2022-09-06
MA43799A (fr) 2021-03-31
MX2018008895A (es) 2019-02-13
KR102799183B1 (ko) 2025-04-21
CN108698991A (zh) 2018-10-23
US20210101890A1 (en) 2021-04-08
WO2017127409A1 (en) 2017-07-27
TWI729059B (zh) 2021-06-01
RU2743747C2 (ru) 2021-02-25
US12139475B2 (en) 2024-11-12
EP3405455A1 (en) 2018-11-28
US10759789B2 (en) 2020-09-01
US20170204087A1 (en) 2017-07-20
IL260635B (en) 2021-04-29
KR20180101565A (ko) 2018-09-12
TW201736345A (zh) 2017-10-16
US20230119895A1 (en) 2023-04-20
EP3405455B1 (en) 2024-02-28
AU2017209023B2 (en) 2021-06-17
ES2985738T3 (es) 2024-11-07
JP6898334B6 (ja) 2021-07-28
AR107398A1 (es) 2018-04-25
RU2018129849A (ru) 2020-02-20
US20190016709A1 (en) 2019-01-17
US20200123136A1 (en) 2020-04-23
US10421748B2 (en) 2019-09-24
CA3011639A1 (en) 2017-07-27
SG11201806153QA (en) 2018-08-30
CN108698991B (zh) 2022-08-23
JP2019502726A (ja) 2019-01-31
RU2018129849A3 (es) 2020-03-11
BR112018014666A2 (pt) 2018-12-26
ZA201804966B (en) 2022-12-21
BR112018014666B1 (pt) 2024-01-02

Similar Documents

Publication Publication Date Title
CY1126855T1 (el) Ενωσεις κυκλικων δινουκλεοτιδιων για τη θεραπευτικη αγωγη καρκινου
EP3618829A4 (en) QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER ASSOCIATED DISORDERS
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
MX378739B (es) Compuestos de 2-oxindol.
EP3634417C0 (en) QUINAZOLINE-PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
EP4017489C0 (en) DGD1202 FOR THE TREATMENT OF KRAS-MUTATED CANCERS
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
HUE050155T2 (hu) 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére
EP3760625C0 (en) BICYCLIC LACTAMS AS PROTEIN KINASE 1 (RIP1) INHIBITORS INTERACTING WITH RECEPTORS FOR TREATMENT E.G. OF INFLAMMATORY DISEASES
MX383652B (es) Moduladores de la vía de estrés integrada.
MY192927A (en) Fused bicyclic compounds for the treatment of disease
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EP3684418C0 (en) COMPOUNDS FOR THE TREATMENT OF CYSTEAMINE-RESPONSIVE DISORDERS
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
EP3263132C0 (en) COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
EA201990400A1 (ru) Соединения и композиции и их применение
EP3565558A4 (en) POLYTHERAPY FOR CANCER TREATMENT
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
EP3405188A4 (en) Treatment for modulating gut microbiota
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
WO2016094374A8 (en) Compositions and methods for treatment of friedreich's ataxia